Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 8—August 2008

Oseltamivir Prescribing in Pharmacy-Benefits Database, United States, 2004–20051

Justin R. Ortiz*2Comments to Author , Laurie Kamimoto*, Ronald E. Aubert†, Jianying Yao†, David K. Shay*, Joseph S. Bresee*, and Robert S. Epstein†
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, GA, USA; †Medco Health Solutions, Inc., Franklin Lakes, New Jersey, USA;

Main Article

Table 2

Oseltamivir prescription rates/100,000 enrollees by age and chronic disease classification, United States, weeks 36–44, 2004 and 2005

Characteristic 2004 2005 Rate ratio (2005/2004) 95% Confidence interval
Age group, y
<1 0.26 10.65 40.7 (5.6–294)
1–4 8.95 65.95 7.4 (6.3–8.6)
5–17 11.12 81.28 7.3 (6.8–7.9)
18–24 19.55 81.42 4.2 (3.8–4.5)
25–49 33.08 120.97 3.7 (3.5–3.8)
50–64 63.33 211.26 3.3 (3.2–3.4)
Chronic disease classification*
Pulmonary 77.66 268.50 3.46 (3.33–3.60)
Immune deficient 67.75 240.16 3.54 (3.21–3.91)
Neurologic 54.57 207.43 3.80 (3.47–4.15)
Cardiac 54.11 196.92 3.64 (3.54–3.74)
Diabetes 50.85 143.85 2.83 (2.64–3.02)
Chronic disease absent
*Rates from chronic disease classification include only enrollees >18 y of age. Except for the chronic disease absent category, all chronic disease classifications were not mutually exclusive. Chronic disease classification is derived from the chronic disease index, which has been validated (10).

Main Article

  1. World Organisation for Animal Health (OIE). Update on avian influenza in animals (type H5). Paris: The Organisation; 2006.
  2. Smith  NM, Bresee  JS, Shay  DK, Uyeki  TM, Cox  NJ, Strikas  RA. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55:142.PubMedGoogle Scholar
  3. World Health Organization. Avian influenza A(H5N1)—update 22: first data on patients from Vietnam, clinical data from Hong Kong 1997, susceptibility of H5N1 viruses to antiviral drugs. Vol. 2006. Geneva: The Organization; 2005.
  4. Wright  T. Roche plans big increase in Tamiflu production. The New York Times; 2005 Nov 10:6.
  5. Brett  AS, Zuger  A. The run on Tamiflu: should physicians prescribe on demand? N Engl J Med. 2005;353:26367. DOIPubMedGoogle Scholar
  6. Centers for Disease Control and Prevention. Update: influenza activity—United States and worldwide, 2005–06 season, and composition of the 2006–07 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2006;55:64853.PubMedGoogle Scholar
  7. Centers for Disease Control and Prevention. Update: Influenza activity—United States and worldwide, 2004–05 season. MMWR Morb Mortal Wkly Rep. 2005;54:6314.PubMedGoogle Scholar
  8. Centers for Disease Control and Prevention. Increased antiviral medication sales before the 2005–06 influenza season—New York City. MMWR Morb Mortal Wkly Rep. 2006;55:2779.PubMedGoogle Scholar
  9. Ortiz  JR, Shay  DK, Liedtke  LA, Bresee  JS, Strausbaugh  LJ. A national survey of the Infectious Diseases Society of America Emerging Infections Network concerning neuraminidase inhibitor prescription practices and pandemic influenza preparations. Clin Infect Dis. 2006;43:4947. DOIPubMedGoogle Scholar
  10. Malone  DC, Billups  SJ, Valuck  RJ, Carter  BL. Development of a chronic disease indicator score using a Veterans Affairs Medical Center medication database. IMPROVE Investigators. J Clin Epidemiol. 1999;52:5517. DOIPubMedGoogle Scholar
  11. Centers for Disease Control and Prevention. Respiratory and enteric virus national trends. Atlanta: The Centers; 2007.

Main Article

1This study was presented, in part, at the Infectious Diseases Society of America annual meeting in Toronto, Ontario, Canada, October 14, 2006, and in poster form at the Options for the Control of Influenza Conference, Toronto, June 17, 2007.

2Current affiliation: University of Washington, Seattle, WA, USA.

Page created: July 12, 2010
Page updated: July 12, 2010
Page reviewed: July 12, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.